Peps
What is Nisotirostide?
Nisotirostide is a selective NPY2 receptor agonist investigated as an adjunct to GLP-1 treatment. The selected publication combines laboratory experiments with a small phase 1 human study.
Biological role or research focus
NPY2 signaling and adjunctive metabolic-treatment research.
An NPY2 agonist is distinct from a GLP-1 agonist. Early combination findings do not validate an unverified supplier preparation.
Role reference: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
Names you may encounter
LY3457263
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Selective NPY2 receptor agonist
- Development name
- LY3457263
- Featured human evidence
- Phase 1 · 65 participants
- Trial registry
- NCT04641312
- Source check
- October 4, 2026 · NLM abstract
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
NPY2 signaling: a different research pathway
The researchers measured selective activation of the NPY2 receptor in laboratory assays. They explored whether this pathway could complement GLP-1 receptor agonism rather than serve as another name for it.
Mouse experiments examined food intake, body composition, weight, glucose, and insulin. These experiments support a development rationale; they cannot establish the magnitude of benefit or the risk profile in people. The human phase 1 component must be interpreted separately.
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
Investigational context & research status
The October 2026 publication describes nisotirostide as under development for adjunctive treatment in type 2 diabetes and obesity. Its clinical component included people already receiving dulaglutide, alongside healthy participants.
This page summarizes that publication, not an independently verified regulatory approval or prescribing reference. A clinical development name does not verify the identity, purity, or suitability of a product sold under that name. No supplier association has been verified for this profile.
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human phase 1 study with separate preclinical experiments · 2026
Discovery-to-clinic phase 1 study
What early safety and weight signals were reported alone and alongside dulaglutide?
- Population / model
- 65 participants in the phase 1 study, including healthy participants and participants with type 2 diabetes already receiving dulaglutide. The abstract does not give subgroup sizes.
- Study design
- Single subcutaneous administration across a range of study exposures; safety, tolerability, pharmacokinetics, and pharmacodynamic assessments. Laboratory and mouse experiments were separate parts of the development program.
- Main finding
- Mean weight difference versus placebo was −0.75 kg with nisotirostide alone, which was not statistically significant. Added to dulaglutide, a difference of up to −2.58 kg versus dulaglutide alone was reported (P<0.05). Nausea and vomiting were the most common adverse events, described as dose-dependent and mild to moderate.
- How to read it
- The human results are reported in kilograms. The paper’s reductions of up to 12% alone and 31% in combination refer to mice; those percentages are not human weight-loss outcomes.
- Limits & context
- Small, early, single-administration research cannot establish sustained effectiveness or long-term safety. Follow-up duration, subgroup sizes, confidence intervals, and detailed allocation methods are not supplied in the abstract. A pharmacokinetic rationale for weekly development is not an established treatment schedule.
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 0 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
No additional records were returned by this limited exact-name search. That is not evidence that no research exists; alternative scientific names may need investigation.
Repeat this PubMed search ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What was observed in the early human study
Nausea and vomiting were the most common reported adverse events and were described as mild to moderate and dose-dependent. The abstract does not provide event percentages or enough subgroup detail to compare tolerability precisely.
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
What remains unknown
A small phase 1 study cannot exclude uncommon harms, establish longer-term tolerability, or resolve risks across different populations and combinations. The phrase “manageable tolerability” in a development report is not a guarantee of safety for an individual.
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Which outcomes came from mice and which came from people?
- Did the study establish sustained benefit beyond a single administration?
- An NPY2 agonist is distinct from a GLP-1 agonist. Early combination findings do not validate an unverified supplier preparation.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is nisotirostide another GLP-1 peptide?
It targets NPY2. The paper investigates combining that separate pathway with GLP-1 receptor agonism; the compounds are not interchangeable.
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
Did people lose 31% of their body weight?
No. That percentage came from a mouse combination experiment. The human abstract reports kilogram differences after a single administration, with no statistically significant monotherapy difference.
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
Does the early result prove sustained weight loss?
No. Longer and larger controlled studies with clearly reported follow-up, clinically meaningful outcomes, and safety assessment are needed.
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
What should researchers look for next?
Subgroup sizes, allocation methods, confidence intervals, observation duration, repeat-exposure outcomes, adverse-event rates, and direct comparisons will help assess whether the early signal persists.
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
What has PepsRadar actually checked?
The NLM abstract and publication metadata. The full text was not reviewed, and this summary has not been reviewed by a medical professional. No exact atomic structure, validated 3D model, or supplier preparation has been verified here.
Source: Nisotirostide discovery and phase 1 study · Molecular Metabolism · 2026 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.